GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Metrics to compare | GRAL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGRALPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.0x | −2.5x | −0.6x | |
PEG Ratio | −0.06 | −0.03 | 0.00 | |
Price/Book | 0.8x | 2.2x | 2.6x | |
Price / LTM Sales | 13.8x | 10.6x | 3.3x | |
Upside (Analyst Target) | 119.1% | 37.2% | 44.8% | |
Fair Value Upside | Unlock | −5.9% | 5.6% | Unlock |